Cefotaxime for Prevention of Infectious Complications in Bacteriuric Men Undergoing Transurethral Prostatic Resection: A Controlled Comparison with Methenamine

Forty-two men with urinary tract infection and benign prostatic hyperplasia were randomized into two groups before transurethral resection. One group (22 patients) received Claforan® (cefotaxime) peroperatively and thereafter daily for five days. In the other group (20 patients), Hiprex® (methenamine hippurate) was given daily from the day before the operation, for a total of six days. All the bacterial isolates were sensitive to cefotaxime. The efficacy of the medication was clinically and bacteriologically evaluated. Postoperative temperature elevation (>38°C) occurred in one of the 22 patients in the cefotaxime group, and in nine of the 20 in the methenamine hippurate group (p